Latest Breaking News On - Myotonic dystrophy foundation annual conference - Page 1 : comparemela.com

Pepgen Reports Third Quarter 2023 Financial Results And Recent Corporate Developments

Pepgen Reports Third Quarter 2023 Financial Results And Recent Corporate Developments
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

CanadaOttawaOntarioBostonMassachusettsUnited statesLaurence wattsJames mcarthurMyotonic dystrophy foundation annual conferenceDrug administrationNasdaqPepgen incGilmartin groupHealth canadaOttawa international conference on neuromuscular diseaseEnhanced delivery oligonucleotide

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 01, 2023 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.

WashingtonDistrict of columbiaUnited statesNew yorkCanadaOttawaOntarioBostonMassachusettsJames mcarthurSarah suttonAshling hollandLaurence wattsPreclinical developmentPepgen incPreclinical development at pepgen

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference - PepGen (NASDAQ:PEPG)

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of

WashingtonDistrict of columbiaUnited statesNew yorkBostonMassachusettsCanadaOttawaOntarioAshling hollandJames mcarthurLaurence wattsMyotonic dystrophy foundation annual conferencePreclinical development at pepgenPreclinical developmentPepgen inc

Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference

SAN DIEGO, Aug. 31, 2023 /PRNewswire/ Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ,.

WashingtonUnited statesSan diegoCaliforniaMike macleanNavjot raiLinkedinAvidity biosciences incPrnewswire avidity biosciences incTwitterMyotonic dystrophy foundation annual conferenceNasdaqAntibody oligonucleotide conjugatesDystrophy foundation annual conferenceSpliceopathy improvementMyotonic dystrophy type